LAVA Therapeutics N.V. (LVTX) Tops Q3 EPS by 15c

LAVA Therapeutics N.V. (NASDAQ: LVTX) reported Q3 EPS of ($0.34), $0.15 better than the analyst estimate of ($0.49).

For earnings history and earnings-related data on LAVA Therapeutics N.V. (LVTX) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Deutsche Bank Starts DexCom (DXCM) at Buy
• Creatd files Form S-1 and reports Q1 2026 financial results